×
About 39,018 results

ALLMedicine™ Colitis Center

Research & Reviews  12,870 results

Safety and efficacy of tofacitinib for treatment of ulcerative colitis: final analysis ...
https://doi.org/10.1111/apt.16712
Alimentary Pharmacology & Therapeutics; Sandborn WJ, Lawendy N et. al.

Dec 3rd, 2021 - Tofacitinib is an oral, small molecule Janus kinase inhibitor for the treatment of ulcerative colitis. We present final data from OCTAVE Open, an open-label, long-term extension study. The primary objective of OCTAVE Open was to assess the safety ...

P004 Steroid-Free Remission in Patients With Ulcerative Colitis Receiving Tofacitinib i...
https://doi.org/10.14309/01.ajg.0000798616.20791.8c
The American Journal of Gastroenterology; Oleg K, Anna K et. al.

Dec 2nd, 2021 - P004 Steroid-Free Remission in Patients With Ulcerative Colitis Receiving Tofacitinib in Real Clinical Practice.|2021|Oleg K,Anna K,Albina L,Anait B,Dmitriy K,|

P006 The Relationship of Histological Remission With the Duration of the Anamnesis Ulce...
https://doi.org/10.14309/01.ajg.0000798624.19339.03
The American Journal of Gastroenterology; Oleg K, Sergey K et. al.

Dec 2nd, 2021 - P006 The Relationship of Histological Remission With the Duration of the Anamnesis Ulcerative Colitis.|2021|Oleg K,Sergey K,Anna K,Albina L,Karina N,|

P009 Assessing the Status Quo: Ulcerative Colitis Monitoring in a Community GI Practice.
https://doi.org/10.14309/01.ajg.0000798636.78132.29
The American Journal of Gastroenterology; Hartman B, Diana H et. al.

Dec 2nd, 2021 - P009 Assessing the Status Quo: Ulcerative Colitis Monitoring in a Community GI Practice.|2021|Hartman B,Diana H,Casey C,|

P037 Effect of Ozanimod Treatment and Discontinuation on Absolute Lymphocyte Count in M...
https://doi.org/10.14309/01.ajg.0000798748.09138.3f
The American Journal of Gastroenterology; Jean-Frederic C, Geert D et. al.

Dec 2nd, 2021 - P037 Effect of Ozanimod Treatment and Discontinuation on Absolute Lymphocyte Count in Moderate-to-Severe Ulcerative Colitis: Results from a Phase 3 Trial.|2021|Jean-Frederic C,Geert D,Peter I,AnnKatrin P,Denesh C,|

see more →

Guidelines  30 results

COVID-19 Pandemic: Which IBD Patients Need to Be Scoped-Who Gets Scoped Now, Who Can Wa...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665406
Journal of Crohn's & Colitis; Ng SC, Mak JWY et. al.

Oct 22nd, 2020 - Endoscopy is an essential component in the management of inflammatory bowel disease [IBD]. There is a risk of SARS-CoV-2 transmission during endoscopic procedures. The International Organization for the study of IBD [IOIBD] has developed 11 positi...

AGA Clinical Practice Update on Diagnosis and Management of Immune Checkpoint Inhibitor...
https://doi.org/10.1053/j.gastro.2020.08.063
Gastroenterology Dougan M, Wang Y et. al.

Oct 21st, 2020 - Immune checkpoint inhibitors (ICIs) have transformed the treatment landscape for oncology, leading to durable remissions in a subset of patients, but also a broad range of potentially life-threatening inflammatory toxicities, many of which involve...

Multinational Association of Supportive Care in Cancer (MASCC) 2020 clinical practice r...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8507388
Supportive Care in Cancer : Official Journal of the Multi... Dougan M, Blidner AG et. al.

Aug 29th, 2020 - Immune-related adverse events (IrAEs) affecting the gastrointestinal (GI) tract and liver are among the most frequent and most severe inflammatory toxicities from contemporary immunotherapy. Inflammation of the colon and or small intestines (enter...

Pharmacological Management of Adult Outpatients With Moderate to Severely Active Ulcera...
https://doi.org/10.1053/j.gastro.2020.03.011
Gastroenterology

Mar 29th, 2020 - Pharmacological Management of Adult Outpatients With Moderate to Severely Active Ulcerative Colitis: Clinical Decision Support Tool.|2020| ,|

Spotlight: Management of Moderate-to-Severe Ulcerative Colitis.
https://doi.org/10.1053/j.gastro.2020.03.012
Gastroenterology Feuerstein JD, Isaacs KL et. al.

Mar 15th, 2020 - Spotlight: Management of Moderate-to-Severe Ulcerative Colitis.|2020|Feuerstein JD,Isaacs KL,Schneider Y,Siddique SM,Falck-Ytter Y,|

see more →

Drugs  735 results see all →

Clinicaltrials.gov  482 results

Extension Study of APD334-003 in Patients With Moderately to Severely Active Ulcerative Colitis
https://clinicaltrials.gov/ct2/show/NCT02536404

Nov 25th, 2021 - The purpose of this study is to determine whether etrasimod (APD334) is a safe and effective treatment for ulcerative colitis after 52 weeks of treatment.

Gene Expression in Chronic Venous Leg Ulcers
https://clinicaltrials.gov/ct2/show/NCT05134597

Nov 25th, 2021 - Chronic Venous Disease (CVD) is a widespread clinical condition widely spread in the western countries, with a prevalence ranging from 10% in adults younger than 30 years of age to nearly 80% for individuals >70 years of age. CVD clinical manifest...

A Study to Evaluate the Effect of Ustekinumab on Cytochrome P450 Enzyme Activities Following Induction and Maintenance Dosing in Participants With Active Crohn's Disease or Ulcerative Colitis
https://clinicaltrials.gov/ct2/show/NCT03358706

Nov 25th, 2021 - The purpose of this study is to evaluate the potential effects of an intravenous (IV) induction and subcutaneous (SC) maintenance administration of ustekinumab on the pharmacokinetic (PK) of a cocktail of representative probe substrates of cytochr...

A Study to Evaluate the Long-term Safety and Efficacy of BMS-986165 in Participants With Crohn's Disease or Ulcerative Colitis
https://clinicaltrials.gov/ct2/show/NCT04877990

Nov 24th, 2021 - The purpose of this study is to evaluate the long-term safety and efficacy of BMS-986165 in participants who have previously been enrolled in a BMS-986165 Phase 2 study for moderate to severe Crohn's disease or moderate to severe Ulcerative Colitis.

A Study to Assess the Safety and Pharmacokinetics of Subcutaneously Administered Golimumab, a Human Anti-TNFα Antibody, in Pediatric Patients With Moderate to Severe Active Ulcerative Colitis
https://clinicaltrials.gov/ct2/show/NCT01900574

Nov 24th, 2021 - This is an open-label (both [participants and investigator] know what treatment participants will receive) and multicenter study. The study is divided into 2 parts: Part 1: pharmacokinetics portion (Week 0 to Week 14); Part 2: study extension (Wee...

see more →

News  1,454 results

Ulcerative colitis: Donor-derived strains predict response in FMT
https://www.mdedge.com/internalmedicine/article/249198/gastroenterology/ulcerative-colitis-donor-derived-strains-predict
Heidi Splete

Nov 30th, 2021 - The Odoribacter splanchnicus strain of human donor-derived bacteria correlated with clinical response to ulcerative colitis in study in which mouse models were colonized with patient-derived strains. Although some recent trials have shown the effe.

Whole-food exclusion diet effective for adult Crohn’s disease
https://www.mdedge.com/internalmedicine/article/249169/gastroenterology/whole-food-exclusion-diet-effective-adult-crohns
Diana Swift

Nov 29th, 2021 - The Crohn’s disease exclusion diet (CDED), with or without partial enteral nutrition (PEN), effectively induced and maintained remission in adults with mild to moderate, biologic-naive CD, a randomized Israeli pilot study found. The authors, led b.

FDA Approves Adjuvant Pembrolizumab for RCC
https://www.onclive.com/view/fda-approves-adjuvant-pembrolizumab-for-rcc

Nov 19th, 2021 - The FDA has approved pembrolizumab (Keytruda) for the adjuvant treatment of patients with renal cell carcinoma (RCC) who are at intermediate-high or high risk of recurrence following nephrectomy, or following nephrectomy and resection of metastati...

Tofacitinib Postmarketing Data Shed Light on JAK Inhibitor Risks
https://www.medscape.com/viewarticle/963183

Nov 17th, 2021 - Additional analyses of a postmarketing trial that was required after the Food and Drug Administration's approval of the Janus kinase inhibitor tofacitinib (Xeljanz, Xeljanz XR) has identified characteristics of older patients with rheumatoid arthr...

Patient Risk, Not Disease Duration, Key to Timing Biologics in IBD
https://www.medscape.com/viewarticle/963195

Nov 17th, 2021 - The decision to Initiate biologics early in the treatment of Crohn's disease (CD) and ulcerative colitis (UC) should be based on complication risk, not on the assumption that earlier treatment produces better results, new research suggests. Result...

see more →

Patient Education  36 results see all →